Global CIS Insulin Market By Type, By Application, By Region and Companies - Industry Segment Outlook, Market Assessment, Competition Scenario, Trends and Forecast 2023-2032
- Published date: May 2023
- Report ID: 67407
- Number of Pages: 387
- Format:
- keyboard_arrow_up
Quick Navigation
Report Overview
“The global CIS insulin market is expected to be worth around USD 593.62 million by 2032 from USD 466 million in 2022, growing at a CAGR of 2.45% during the forecast period 2021 to 2031.”
CIS insulin controls the metabolism of fats and carbohydrates by endorsing glucose absorption from the blood to fat tissue and skeletal muscles and affecting fat to store rather than use for energy. Produced by beta cells, insulin is the most significant peptide hormone in the pancreas. Insufficient production of insulin leads to sugar buildup in blood cells causing diabetes. The global CIS insulin market is anticipated to boost due to leading factors, including a rising number of diabetes cases globally, eating habits of individuals, and varying lifestyles causing health disorders, including other metabolic diseases and obesity is anticipated to fuel for the CIS insulin market growth.
Insulin is the body’s primary anabolic hormone produced in the pancreas by beta cells. It controls metabolism by promoting the preoccupation of glucose into the skeletal muscle cells, liver, and fat from the blood.
Global CIS Insulin Market Scope:
Product Analysis
Based on the product global CIS Insulin market is classified into long-acting, rapid-acting, short-acting, premixed, and intermediate-acting. Rapid-acting CIS insulin accounts for the largest market share and is projected to register a CAGR of 2.4%. Rapid-acting insulin swaps the insulin usually produced by the human body—serving sugar in blood cells to other body tissues. Rapid-acting insulin works very fast to minimalize the increase in blood sugar post-eating, and its effect continues for hours. This type of insulin is frequently used to maintain blood glucose for longer. It is utilized to energy constrain the liver from creating more sugar, another factor making them an ideal choice amongst patients and physicians. These factors may boost the demand for the rapid-acting CIS insulin segment in 2023-2032.
Application Analysis
Based on application, the market is divided into Type I Diabetes and Type II Diabetes segments.
The presence of a wide range of products in the Type II Diabetes segment and the high prevalence of Type II Diabetes supplements the growth of this CIS insulin market.
Among these, the type I segment registered a CAGR of 2.2% in 2022. The growing diagnosis degree of Type I helps boost the segment’s growth. People with type I diabetes use insulin to regulate their blood glucose levels. Around 10.2% of all diabetic patients have type I diabetes. It is anticipated that growing insulin production in advanced countries and several new products will boost the segment’s growth.
Key Market Segments:
By Type
- Rapid Acting
- Long Acting
- Short Acting
- Intermediate Acting
- Premixed
By Application
- Type I Diabetes
- Type II Diabetes
Market Dynamics:
Drivers
It is owing to the growing number of diabetes patients, eating habits of individuals, and changing lifestyles causing health disorders. Increasing government investments and initiatives to deliver a high-quality diagnosis, mainly across developed nations, including the US, China, and the UK, will create the CIS insulin market size in the upcoming ye. This includes obesity and other metabolic diseases, surging investments in R&D, innovations in insulin products, and a rise in CIS insulin application into type I and type II diabetes. Ars.
Restraints:
Despite optimistic growth projections, the global CIS insulin market is facing several problems that may somewhat hamper its growth. Some factors comprise the negative effect of the need for insulin therapy, such as pain and hypoglycemia at the site of injection, which may influence some individuals’ use. Other disadvantages, including electrolyte imbalance, weight gain, and in rare cases, decreased compliance, high nocturnal glucose levels, and peripheral hyperinsulinemia, also lower the development of the CIS insulin market. Growing insulin resistance, mainly amongst obese individuals, can restrain the market’s growth.
Regional Analysis
Geographically, North America holds 34.6% of the largest CIS insulin market share globally, followed by Europe and Asia. The high occurrence rate of metabolic diseases and diabetes, including obesity, is the main driver for the CIS insulin market. Moreover, constant R&D in this field for effective products would act as an assisting feature for market growth.
Asia-Pacific is detected to be a developing market for the CIS insulin market owing to the leading pharmaceutical companies selecting Asia-Pacific as the producing destination. Europe is the 2nd largest market due to comprehensive government initiatives regulating price and production acting as the feature for the insulin market growth. South American countries, including Mexico and Brazil, are the regions that have substantial potential for growth for insulin due to emerging medical infrastructure, a rise in population, and high disposable income. Furthermore, the increasing population in countries including India, China, etc., would consequence in the market development for the CIS insulin market.
Key Regions and Countries covered in the report:
- North America
- US
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Russia
- Spain
- Rest of Europe
- APAC
- China
- Japan
- South Korea
- India
- Rest of Asia-Pacific
- South America
- Brazil
- Argentina
- Rest of South AmerMENU
- MEA
- GCC
- South Africa
- Israel
- Rest of MEA
legalBoehringer Ingelheim, Biocon, and several local companies produce biosimilars, including Farmak and Indrar. More than half of the CIS insulin market share is captured by local producers. The key players accept vital strategies, including geographical expansion, product development, mergers and acquisitions, and many other methods.
Major CIS insulin market players include…..
Market Key Players:
- Sanofi
- Bristol-Myers Squibb
- Eli Lilly
- Novartis
- Boehringer Ingelheim
- Takeda Pharmaceuticals
- Biocon
- Merck KGaA
- Dongbao Enterprise Group Co. Ltd.
- Other key players
Recent Developments
In June 2022- Lilly presented the new device of action data for further new analyses of Mounjaro™ (tirzepatide) injection for treating adults with type II diabetes at the 82nd Scientific Session of the American Diabetes Association’s®.
In November 2021 – Novo Nordisk publicized the acquisition of Dicerna Pharmaceuticals (Dicerna) to discover. Develop RNAi therapies using Dicerna’s proprietary GalXC™ RNAi platform technology.
In February 2022 — Novartis India Limited (NIL) announced an exclusive sales and distribution agreement with Dr. Reddy’s Laboratories (Dr. Reddy’s) for a few of its Established Medicines, including the Voveran range, the Calcium range, and Methergine.
In January 2022- Bristol Myers Squibb and Century Therapeutics publicized a license and collaboration agreement to commercialize and develop up to four induced pluripotent stem cell (“iPSC”) derived, engineered natural killer cell (“or T cell (“iT”) programs for hematologic malignancies and solid tumors.
For the CIS insulin market research study, the following years have been considered to estimate the market size:
Attribute Report Details Market Size in 2022
USD 466 million
Growth Rate
USD 593.62 million
Forecast Value in 2032
2.45%
Historical Years
2016-2020
Base Year
2021
Estimated Year
2022
Short Term Projection Year
2028
Projected Year
2023
Long Term Projection Year
2032
Report Coverage
Competitive Landscape, Revenue analysis, Company Share Analysis, Manufacturers Analysis, Volume by Manufacturers, Key Segments, Key company analysis, Market Trends, Distribution Channel, Market Dynamics, COVID-19 Impact Analysis, strategy for existing players to grab maximum market share, and more.
Regional Scope
North America, Europe, Asia-Pacific, South America, Middle East & Africa
Country Scope
United States, Canada and Mexico, Germany, France, UK, Russia and Italy, China, Japan, Korea, India and Southeast Asia, Brazil, Argentina, Colombia etc.Saudi Arabia, UAE, Egypt, Nigeria and South Africa
- Sanofi Company Profile
- Bristol-Myers Squibb
- Eli Lilly
- Novartis AG Company Profile
- Boehringer Ingelheim
- Takeda Pharmaceuticals
- Biocon
- Merck KGaA Company Profile
- Dongbao Enterprise Group Co. Ltd.
- Other key players
- settingsSettings
Our Clients
Single User $6,000 $3,999 USD / per unit save 24% | Multi User $8,000 $5,999 USD / per unit save 28% | Corporate User $10,000 $6,999 USD / per unit save 32% | |
---|---|---|---|
e-Access | |||
Report Library Access | |||
Data Set (Excel) | |||
Company Profile Library Access | |||
Interactive Dashboard | |||
Free Custumization | No | up to 10 hrs work | up to 30 hrs work |
Accessibility | 1 User | 2-5 User | Unlimited |
Analyst Support | up to 20 hrs | up to 40 hrs | up to 50 hrs |
Benefit | Up to 20% off on next purchase | Up to 25% off on next purchase | Up to 30% off on next purchase |
Buy Now ($ 3,999) | Buy Now ($ 5,999) | Buy Now ($ 6,999) |